Splash Beverage Acquires Global Rights to CannEpil Therapy
FORT LAUDERDALE, Fla., July 7, 2026 Splash Beverage Group, Inc. has announced the acquisition of exclusive global licensing rights...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
FORT LAUDERDALE, Fla., July 7, 2026 Splash Beverage Group, Inc. has announced the acquisition of exclusive global licensing rights...
NEW YORK, July 7, 2026 The American Parkinson Disease Association (APDA) has announced the launch of “Bridging Mental Health...
